Sort   by:  
 Page size 
UnknownSequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Not available
S-EPMC8637474 | biostudies-literature
UnknownA prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).
Not available
S-EPMC9773621 | biostudies-literature
UnknownGABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer.
Not available
S-EPMC12359486 | biostudies-literature
UnknownSelective treatment pressure in colon cancer drives the molecular profile of resistant circulating tumor cell clones.
Not available
S-EPMC7869222 | biostudies-literature
UnknownSurvival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review.
Not available
S-EPMC9405894 | biostudies-literature
UnknownOncological Outcomes after Liver Venous Deprivation for Colorectal Liver Metastases: A Single Center Experience.
Not available
S-EPMC7826613 | biostudies-literature
UnknownManagement of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.
Not available
S-EPMC10839736 | biostudies-literature
UnknownPlasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma.
Not available
S-EPMC8774261 | biostudies-literature
UnknownOptimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Not available
S-EPMC9928940 | biostudies-literature
UnknownThe p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner.
Not available
S-EPMC5315499 | biostudies-literature
Sort   by:  
 Page size